Hospitalizations for several common diseases—including septicemia (serious bloodstream infection), fluid and electrolyte disorders, renal failure, urinary tract infections, and skin and tissue infections—have been linked for the first time with short-term exposure to fine particulate air pollution (PM2.5), according to a comprehensive new study led by Harvard T.H. Chan School of Public Health.
Cancer death rates continued to decline in men, women, and children in the United States from 1999 to 2016, according to the latest Annual Report to the Nation on the Status of Cancer.
Scientists at the International Agency for Research on Cancer (IARC), in collaboration with researchers at the Protestant Clinic of Lyon (France), the Portuguese Oncology Institute of Porto (Portugal), and Lomonosov Moscow State University (Russian Federation), have developed a simple, sensitive, and specific urine test (called UroMuTERT) that is capable of detecting urothelial cancer (carcinoma of the bladder and of the upper urinary tract).
Nearly half of all childhood cancers are not being diagnosed globally, according to a new modeling study led by Harvard T.H. Chan School of Public Health.
IARC publication highlights variations in cancer incidence, survival, and mortality that exist between countries
A new Scientific Publication from the International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization (WHO), has examined the global problem of social inequalities in cancer, highlighting the large variations in cancer incidence, survival, and mortality that exist between countries.
A research team led by scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has determined how several antibodies induced by Epstein-Barr virus (EBV), a herpesvirus that causes infectious mononucleosis and is associated with certain cancers, block infection of cells grown in the laboratory.
With Antibody-Drug Combination, NIAID Scientists Improve Outcomes of Bone Marrow Transplants in Mice
In a new paper published February 6 in Nature Communications, researchers from NIAID and Harvard University describe a way to better prepare a recipient to tolerate bone marrow donation, using an antibody-drug conjugate that combines a cell-targeting antibody with a cell toxin, which the antibody carries as cargo.